# A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

> **NCT05989542** · PHASE3 · RECRUITING · sponsor: **Beijing Pearl Biotechnology Limited Liability Company** · enrollment: 136 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** PLB1001

## Key facts

- **NCT ID:** NCT05989542
- **Lead sponsor:** Beijing Pearl Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-16
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05989542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05989542, "A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05989542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*